Kenvue (KVUE) Q2 Sales Drop 4%

Kenvue (NYSE:KVUE), the consumer health company best known for brands like Tylenol and Band-Aid, reported its earnings for the second quarter on August 7, 2025. The main news from the release: Non-GAAP earnings per share reached $0.29, narrowly beating analyst forecasts of $0.28 (non-GAAP), but GAAP revenue fell to $3.839 billion, slightly below GAAP estimates of $3.85 billion and down from $4.00 billion (GAAP) a year earlier. The period also highlighted positive free cash flow (non-GAAP), even as weak sales impacted all business lines. Management reduced its FY2025 outlook, signaling that tougher times may lie ahead for the company. Source: Analyst estimates for the quarter provided by FactSet. Kenvue develops and markets consumer health products across a range of categories. Its lineup covers essential over-the-counter medicines, personal care items, and wellness products -- including household brands like Tylenol (pain relief and fever reducer), Neutrogena (skin care), and Listerine (mouthwash).Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool